Development of a live, attenuated, recombinant vaccine for Brucellosis

Simple item page
dc.contributor.assigneeVirginia Tech Intellectual Properties, Inc.en
dc.contributor.inventorBoyle, Stephen M.en
dc.contributor.inventorSchurig, Gerhardt G.en
dc.contributor.inventorSriranganathan, Nammalwaren
dc.contributor.inventorBandara, Aloka B.en
dc.date.accessed2016-08-19en
dc.date.accessioned2016-08-24T17:54:46Zen
dc.date.available2016-08-24T17:54:46Zen
dc.date.filed2005-10-11en
dc.date.issued2008-04-29en
dc.description.abstractA recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to the Brucella species is identified by detecting a genetic sequence for carboxyl-terminal (i.e. tail-specific) protease activity in a biological sample.en
dc.format.mimetypeapplication/pdfen
dc.identifier.applicationnumber11246957en
dc.identifier.patentnumber7364745en
dc.identifier.urihttp://hdl.handle.net/10919/72583en
dc.identifier.urlhttp://pimg-fpiw.uspto.gov/fdd/45/647/073/0.pdfen
dc.language.isoen_USen
dc.publisherUnited States Patent and Trademark Officeen
dc.subject.cpcA61K39/099en
dc.subject.cpcA61K2039/522en
dc.subject.cpcC12Q1/689en
dc.subject.cpcC12N1/36en
dc.subject.cpcC12N9/52en
dc.subject.uspc424/252.1en
dc.subject.uspcother435/471en
dc.subject.uspcother435/477en
dc.titleDevelopment of a live, attenuated, recombinant vaccine for Brucellosisen
dc.typePatenten
dc.type.dcmitypeTexten
dc.type.patenttypeutilityen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
7364745.pdf
Size:
3.47 MB
Format:
Adobe Portable Document Format
Download

Collections

Virginia Tech Patents